Midissia is a clinical stage immunotherapy start-up, developing personalized dendritic cancer vaccines through “immunogenic intensification” by combining the vaccines with select checkpoint inhibitors/immune modulators. Its lead asset the AdHER2 vaccine targets HER2 positive cancers . Midissia is the recent recipient of the Cancer Discovery Incubator Award by Immunomic Therapeutics, a major vaccine player.